PE20251386A1 - Conjugados anticuerpo-farmaco y sus usos - Google Patents

Conjugados anticuerpo-farmaco y sus usos

Info

Publication number
PE20251386A1
PE20251386A1 PE2024001907A PE2024001907A PE20251386A1 PE 20251386 A1 PE20251386 A1 PE 20251386A1 PE 2024001907 A PE2024001907 A PE 2024001907A PE 2024001907 A PE2024001907 A PE 2024001907A PE 20251386 A1 PE20251386 A1 PE 20251386A1
Authority
PE
Peru
Prior art keywords
antibody
moiety attached
conjugate
drug conjugates
tumors
Prior art date
Application number
PE2024001907A
Other languages
English (en)
Spanish (es)
Inventor
Warren Viricel
Original Assignee
Mablink Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mablink Bioscience filed Critical Mablink Bioscience
Publication of PE20251386A1 publication Critical patent/PE20251386A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2024001907A 2022-03-11 2023-03-10 Conjugados anticuerpo-farmaco y sus usos PE20251386A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22305279 2022-03-11
PCT/EP2023/056097 WO2023170247A1 (en) 2022-03-11 2023-03-10 Antibody-drug conjugates and their uses

Publications (1)

Publication Number Publication Date
PE20251386A1 true PE20251386A1 (es) 2025-05-22

Family

ID=80979142

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001907A PE20251386A1 (es) 2022-03-11 2023-03-10 Conjugados anticuerpo-farmaco y sus usos

Country Status (17)

Country Link
US (2) US20250302978A1 (cg-RX-API-DMAC7.html)
EP (2) EP4741423A2 (cg-RX-API-DMAC7.html)
JP (2) JP7706668B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240168351A (cg-RX-API-DMAC7.html)
CN (1) CN119173279A (cg-RX-API-DMAC7.html)
AU (2) AU2023231442B2 (cg-RX-API-DMAC7.html)
CA (1) CA3245732A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002655A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024012022A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240375A (cg-RX-API-DMAC7.html)
DK (1) DK4489788T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000178A (cg-RX-API-DMAC7.html)
IL (1) IL314828A (cg-RX-API-DMAC7.html)
JO (1) JOP20240199A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024011013A (cg-RX-API-DMAC7.html)
PE (1) PE20251386A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023170247A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240091372A1 (en) * 2022-07-19 2024-03-21 Seoul National University R&Db Foundation Anti-doppel antibody drug conjugates
AU2024263367A1 (en) 2023-04-27 2025-11-13 CSPC Megalith Biopharmaceutical Co., Ltd. Antibody-drug conjugate
EP4534101A1 (en) * 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
EP4534102A1 (en) * 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
FR3164899A1 (fr) * 2024-07-24 2026-01-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
CN120737008B (zh) * 2025-09-04 2025-11-11 韶远科技(上海)有限公司 一种(S)-4-[2-(Boc-氨基)-1-羟基乙基]-2-硝基苯酚及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN105777907B (zh) 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
MA50265A (fr) * 2017-09-18 2020-07-29 Sutro Biopharma Inc Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
EP3700577A1 (en) 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
CN112125915A (zh) 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
MX2023011630A (es) * 2021-03-30 2024-01-24 Mablink Bioscience Enlace autorreactivo activado por enzima que tiene propiedades fisicoquimicas y farmacologicas mejoradas.

Also Published As

Publication number Publication date
DK4489788T3 (da) 2026-08-03
JP2025148380A (ja) 2025-10-07
CN119173279A (zh) 2024-12-20
JP7706668B2 (ja) 2025-07-11
IL314828A (en) 2024-10-01
CR20240375A (es) 2025-01-06
CA3245732A1 (en) 2023-09-14
AU2023231442B2 (en) 2026-07-02
CO2024012022A2 (es) 2024-09-19
EP4489788B1 (en) 2026-06-17
AU2023231442A1 (en) 2024-09-26
KR20240168351A (ko) 2024-11-29
EP4489788A1 (en) 2025-01-15
US20260232826A1 (en) 2026-08-13
MX2024011013A (es) 2024-09-17
JP2025509142A (ja) 2025-04-11
EP4741423A2 (en) 2026-05-13
DOP2024000178A (es) 2024-11-29
CL2024002655A1 (es) 2025-05-23
US20250302978A1 (en) 2025-10-02
AU2026205135A1 (en) 2026-07-16
WO2023170247A1 (en) 2023-09-14
JOP20240199A1 (ar) 2024-09-11

Similar Documents

Publication Publication Date Title
MX2023001648A (es) Conjugado de anticuerpo y farmaco.
PE20230467A1 (es) Conjugados de anticuerpo y farmaco de eribulina anti-mesotelina y metodos de uso
PE20241299A1 (es) Derivados de exatecan y sus conjugados anticuerpo-farmaco
ES2975330T3 (es) Compuestos que comprenden un enlazador para aumentar la estabilidad del trans-cicloocteno
BR112023001359A2 (pt) Conjugado de anticorpo-fármaco anti-cd79b, método de preparação do mesmo e uso farmacêutico do mesmo
PE20242107A1 (es) Conjugados que comprenden fosforo (v) y una fraccion molecular de droga
PE20220764A1 (es) Conjugados de anticuerpo y farmaco
PE20191539A1 (es) Conjugados anticuerpo-droga para ablacion de celulas madre hematopoyeticas
CL2022003411A1 (es) Conjugados anticuerpo biespecífico-fármaco dirigidos a egfr y muc1 y sus usos
CO2024006160A2 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este
CL2023001755A1 (es) Compuestos farmacéuticos.
AR117657A1 (es) Conjugados de fármaco que comprenden anticuerpos y derivados de ecteinascidina
CL2024003536A1 (es) Conjugados de anticuerpo-fármaco de compuestos antineoplásicos y usos de los mismos.
CL2024002655A1 (es) Conjugados anticuerpo-fármaco y sus usos
UY38520A (es) Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos
CO2025008047A2 (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
MX2020010201A (es) Conjugado de farmaco citotoxico y forma de profarmaco de dicho conjugado.
CO2024003299A2 (es) Conjugado anticuerpo-fármaco anti-cd37
AR131524A1 (es) Conjugados de anticuerpos-fármacos b7h3
UY39681A (es) Derivados de ciclobutilo 1,3–sustituidos y sus usos
CL2023003905A1 (es) Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico
PE20251184A1 (es) Conjugados anticuerpo-farmaco 5t4 y usos de los mismos
MX2023008341A (es) Enlazadores de ésteres de doble escisión para conjugados anticuerpo-fármaco.
BR112023021189A2 (pt) Agentes radioterapêuticos que têm o receptor de folato como alvo e uso do mesmo
Pettit et al. Antineoplastic agents. 604. The path of quinstatin derivatives to antibody drug conjugates